Fig. 3From: Clinical and molecular genetic risk determinants in adult long QT syndrome type 1 and 2 patientsCumulative incidence of cardiac events in LQT2 patients by mutation before initiation of β-blocker treatment at the age of 18–40 yearsBack to article page